Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
29 Results for "
Brown adipose tissue
" in MedChemExpress (MCE) Product Catalog:
Products (29)
29 Results for "Brown adipose tissue" in MCE Product Catalog:
28
28 Publications Verification
Target:
Research Areas:
CL316243 is a highly potent selective β3-adrenoceptor agonist with a EC50 of 3 nM, but is an extremely poor to β1/2- receptors .CL316243 is a effective stimulant of adipocyte lipolysis and increases brown adipose tissue thermogenesis and metabolic rate . CL316243 has the potential for the treatment obesity, diabetes and urge urinary incontinence .
28
28 Publications Verification
Target:
Research Areas:
CL316243 free acid is a highly potent selective β3-adrenoceptor agonist with a EC50 of 3 nM, but is an extremely poor to β1/2- receptors. CL316243 free acid is a effective stimulant of adipocyte lipolysis and increases brown adipose tissue thermogenesis and metabolic rate. CL316243 free acid has the potential for the treatment obesity, diabetes and urge urinary incontinence .
1
1 Cited Publications
Cat. No.: HY-N0593S
CAS No.: 112076-61-6
1
1 Cited Publications
Cat. No.: HY-N0468
CAS No.: 63279-13-0
Category:
Terpenoids Metabolic Disease Diterpenoids Plants Other Families Extract Disease Research Fields Sweeteners Food Research
Target:
1
1 Cited Publications
Category:
Target:
Target:
Research Areas:
Glycerol kinase, microorganism (GyK) acts as a NR4A1 inhibitor with enzymatic activity. It directly binds to and inhibits the transcription factor NR4A1, thereby negatively regulating hepatic gluconeogenesis and reducing blood glucose levels. Glycerol kinase, microorganism positively regulates UCP1 expression via partial dependence on the β-adrenergic receptor-cAMP-CREB pathway, promotes browning of white adipose tissue and thermogenesis, and further modulates intracellular fatty acid composition and energy metabolism. In diabetic mouse models, overexpression of Glycerol kinase effectively antagonizes NR4A1-induced hyperglycemia, demonstrating potential for improving glucose homeostasis. Glycerol kinase, microorganism can be used for studies on diabetes and obesity .
Cat. No.: HY-W012974
CAS No.: 144-90-1
Synonyms: β-Aminoisobutyric acid; BAIBA
Category:
Cardiovascular Disease Ketones, Aldehydes, Acids Disease markers Endocrine diseases Nervous System Disorder Endogenous metabolite Disease Research Fields
Target:
Category:
Cat. No.: HY-116003
CAS No.: 263399-35-5
Target:
Cat. No.: HY-P991736
Target:
Research Areas:
Category:
Target:
Cat. No.: HY-N0593S1
CAS No.: 52840-14-9
Cat. No.: HY-N0593S3
CAS No.: 52886-37-0
Synonyms: Cholanoic Acid-13C; Desoxycholic acid-13C
Cat. No.: HY-N0593S2
CAS No.: 2483832-09-1
Synonyms: Cholanoic acid-d6; Desoxycholic acid-d6
Target:
Research Areas:
ZW290 is a compound to activate brown adipose tissue (BAT) thermogenic function. ZW290 increases the expression of uncoupling Protein 1 (UCP1) protein and inhibits ATP synthesis in BAT .
Cat. No.: HY-N0468R
CAS No.: 63279-13-0
Category:
Cat. No.: HY-162302
Target:
Research Areas:
NMY1009 is a lipophilic C8-hydrocarbon chain conjugated analog that links mitochondrial uncouplers via ether linkages. NMY1009 can be released and enter the mitochondrial matrix and intermembrane space, thereby targeting mitochondrial uncoupler to adipose tissue and increasing energy expenditure in brown and white adipose tissue .
Cat. No.: HY-11032
CAS No.: 902750-48-5
Target:
Research Areas:
SM-350300 is a glucoprotein. SM-350300 stimulates lipolysis in white adipocytes by activating the cyclic AMP (cAMP) pathway, and upregulates the expression of lipolytic enzymes and uncoupling proteins (UCP1, UCP3) in brown adipose tissue (BAT) and white adipose tissue (WAT). SM-350300 reduces body weight by decreasing carcass fat while increasing lean muscle mass in metabolic disorder models. SM-350300 can be used for the study of metabolic disorders including obesity, type 2 diabetes, and cachexia .
Cat. No.: HY-126969
CAS No.: 870095-15-1
Target:
Research Areas:
C333H is a selective PPARγ modulator with insulin-sensitizing and hypoglycemic activities. C333H exhibits similar insulin-sensitizing effects to thiazolidinediones (TZDs) in diabetic mouse models without significantly increasing body weight or adipose tissue weight. C333H increases circulating high molecular weight adiponectin isoform levels in diabetic db/db mice, reduces serine phosphorylation of PPARγ 273 in brown adipose tissue, and selectively modulates the expression of specific PPARγ target genes in adipose tissue. Express. C333H exhibits weak recruitment of co-activators and weak dissociation of co-repressors in vitro. These properties suggest that C333H may be a potential inhibitor of type 2 diabetes .
Cat. No.: HY-165098
CAS No.: 84796-61-2
Synonyms: β-Aminoisobutyric acid sodium salt; BAIBA sodium salt
Target:
Research Areas:
3-Aminoisobutyric acid (β-Aminoisobutyric acid) sodium salt has anti-inflammatory and antioxidant effects. 3-Aminoisobutyric acid sodium salt increases the expression of brown adipocyte-specific genes in white adipose tissue and fatty acid β-oxidation in hepatocytes. 3-Aminoisobutyric acid sodium salt attenuates insulin resistance and inflammation induced by palmitate or a high fat diet via an AMPK–PPARδ-dependent pathway in mice. 3-Aminoisobutyric acid sodium salt is a catabolic metabolite of thymine and valine in skeletal muscle .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
